CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
3.440
-0.320 (-8.51%)
At close: May 15, 2026, 4:00 PM EDT
3.400
-0.040 (-1.16%)
After-hours: May 15, 2026, 7:45 PM EDT
CervoMed Employees
CervoMed had 15 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
15
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$139,268
Profits / Employee
-$2,002,433
Market Cap
31.85M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 15 | 0 | - |
| Dec 31, 2024 | 15 | 7 | 87.50% |
| Dec 31, 2023 | 8 | 4 | 100.00% |
| Mar 31, 2023 | 4 | - | - |
| Dec 31, 2022 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Evaxion | 46 |
| Senti Biosciences Holdings | 39 |
| Palatin Technologies | 29 |
| Boundless Bio | 28 |
| Daré Bioscience | 24 |
| Veru Inc. | 20 |
| Tevogen Bio Holdings | 18 |
| BriaCell Therapeutics | 16 |
CRVO News
- 25 days ago - CervoMed presents neflamapimod MRI data - TheFly
- 25 days ago - CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies - GlobeNewsWire
- 5 weeks ago - CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting - GlobeNewsWire
- 7 weeks ago - CervoMed Transcript: The 38th Annual Roth Conference - Transcripts
- 2 months ago - CervoMed’s neflamapimod shows efficacy in dementia with DLB - TheFly
- 2 months ago - CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod's Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer's Disease Co-Pathology - GlobeNewsWire
- 2 months ago - CervoMed price target lowered to $11 from $19 at Roth Capital - TheFly
- 2 months ago - CervoMed price target raised to $21 from $15 at Chardan - TheFly